Anthony DiGiandomenico - 30 Jan 2023 Form 4 Insider Report for ENDRA Life Sciences Inc. (NDRA)

Role
Director
Signature
/s/ Anthony DiGiandomenico by Mark Busch, attorney-in-fact
Issuer symbol
NDRA
Transactions as of
30 Jan 2023
Net transactions value
$0
Form type
4
Filing time
01 Feb 2023, 19:30:27 UTC
Previous filing
30 Mar 2022
Next filing
03 May 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NDRA Stock Options Award $0 +9,621 $0.000000 9,621 30 Jan 2023 Common Stock 9,621 $4.02 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This stock option grant becomes exercisable in three equal annual installments beginning January 30, 2024.